Clinical Consensus Statement: Perioperative Management of Prothrombotics, Antiplatelets, Anticoagulants, DMARDs and Biologics in Elective Podiatric Surgery

临床共识声明:择期足病手术中促血栓药物、抗血小板药物、抗凝药物、DMARDs 和生物制剂的围手术期管理

阅读:2

Abstract

INTRODUCTION: A substantial body of literature exists on the perioperative management of pharmacological agents specifically prothrombotic agents, antiplatelets, anticoagulants and disease-modifying antirheumatic drugs (DMARDs) aimed at mitigating risks associated with both the medications themselves and the comorbidities they treat. However, a clear and consistent consensus on best practice is either lacking or poorly defined especially in foot surgery. To address this gap, a working group of podiatric surgeons convened to develop a Clinical Consensus Statement (CCS) for the perioperative management of these drugs in foot and ankle surgery. METHOD: A five-member panel identified four key areas of interest: prothrombotic agents, antiplatelets, anticoagulants and disease-modifying antirheumatic drugs. They conducted a comprehensive literature review to assess the available data and identify evidence gaps, ultimately formulating nineteen questions grouped within these areas using a modified Delphi method. These questions were presented to delegates at the 2022 Faculty of Podiatric Surgery (FoPS) Conference. RESULTS: The recommendations from the clinical consensus statement are summarised in Appendix 1 highlighting the strength of each recommendation. Although more high-level evidence is needed to inform decision-making in this area, this consensus statement has utilised the available evidence base and reflects current practice. Rather than providing a definitive guideline, it provides valuable interim guidance for elective foot surgery, however, does not replace local trust policies and guidelines.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。